Secondary invasive fungal infection in hospitalised patients with COVID‐19 in the United States
Open Access
- 13 March 2023
- Vol. 66 (6), 527-539
- https://doi.org/10.1111/myc.13579
Abstract
BackgroundInvasive fungal infections (IFIs) have been identified as a complication in patients with Coronavirus disease 2019 (COVID-19). To date, there are few US studies examining the excess humanistic and economic burden of IFIs on hospitalised COVID-19 patients. ObjectivesThis study investigated the incidence, risk factors, clinical and economic burden of IFIs in patients hospitalised with COVID-19 in the United States. Patients/MethodsData from adult patients hospitalised with COVID-19 during 01 April 2020-31 March 2021 were extracted retrospectively from the Premier Healthcare Database. IFI was defined either by diagnosis or microbiology findings plus systemic antifungal use. Disease burden attributable to IFI was estimated using time-dependent propensity score matching. ResultsOverall, 515,391 COVID-19 patients were included (male 51.7%, median age: 66 years); IFI incidence was 0.35/1000 patient-days. Most patients did not have traditional host factors for IFI such as hematologic malignancies; COVID-19 treatments including mechanical ventilation and systemic corticosteroid use were identified as risk factors. Excess mortality attributable to IFI was estimated at 18.4%, and attributable excess hospital costs were $16,100. ConclusionsInvasive fungal infection incidence was lower than previously reported, possibly due to a conservative definition of IFI. Typical COVID-19 treatments were among the risk factors identified. Furthermore, diagnosis of IFIs in COVID-19 patients may be complicated because of the several non-specific shared symptoms, leading to underestimation of the true incidence rate. The healthcare burden of IFIs was significant among COVID-19 patients, including higher mortality and greater cost.Keywords
Funding Information
- Astellas Pharma Global Development
This publication has 30 references indexed in Scilit:
- COVID‐19 associated pulmonary aspergillosisMycoses, 2020
- Emerging Invasive Fungal Infections: Clinical Features and Controversies in Diagnosis and Treatment ProcessesInfection and Drug Resistance, 2020
- Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research ConsortiumClinical Infectious Diseases, 2019
- Global and Multi-National Prevalence of Fungal Diseases—Estimate PrecisionJournal of Fungi, 2017
- Innate and Adaptive Immune Defects in Chronic Pulmonary AspergillosisJournal of Fungi, 2017
- Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trialThe Lancet, 2015
- Fungal diagnosis: how do we do it and can we do better?Current Medical Research and Opinion, 2013
- Epidemiology of invasive fungal infections in the intensive care unit: results of a multicenter Italian survey (AURORA Project)Infection, 2013
- Aspergillosis in Intensive Care Unit (ICU) patients: epidemiology and economic outcomesBMC Infectious Diseases, 2013
- Immortal time bias in critical care research: Application of time-varying Cox regression for observational cohort studies*Critical Care Medicine, 2009